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Type 1 diabetes in the nonobese diabetic (NOD) mouse arises as a consequence of T cell-mediated destruction of
the insulin-producing b cells of the pancreas. Although little is known of the events that initiate and
subsequently drive b-cell destruction it is clear that the entire process is under complex genetic control. At
present 19 loci have been mapped that influence the development of diabetes either at the level of initiation of
insulitis or at the level of progression from insulitis to overt diabetes, or both. Previously, we have mapped one
of these loci, Idd3, to a 0.35-cM interval on proximal mouse chromosome 3. In the present study we have
narrowed the map position of this locus to an interval of 0.15 cM by a combination of novel congenic strains
and an ancestral haplotype analysis approach. We have constructed a physical contig in bacterial artificial
chromosome (BAC) clones across the minimal interval. Restriction mapping of the BAC contig placed the
maximum size of the Idd3 interval at 780 kb between the markers D3Nds36 and D3Nds76. To refine further the
Idd3 interval we developed a series of novel single nucleotide polymorphisms (SNPs) and carried out haplotype
analysis on DNA from mouse strains known to carry either Idd3 susceptibility or protective alleles. This
haplotype analysis identified a 145-kb segment of ancestral DNA between the microsatellite marker D3Nds6 and
the SNP 81.3. One haplotype of this ancestral segment of DNA is found in mouse strains carrying an Idd3
susceptibility allele and another is found in mouse strains carrying an Idd3 protective allelle. Within the 780-kb
congenically defined interval this 145-kb segment represents the most likely location for Idd3. The Il2 gene,
which encodes the cytokine interleukin 2 (IL2), maps to this interval and is a strong candidate for Idd3. To
investigate whether sequence variation exists in the promoter region of the Il2 gene, which might alter its
expression, we sequenced the promoter region of the Il2 gene from mouse strains carrying either an Idd3
susceptibility or resistance allele. Two sequence variants were identified, neither of which fell in known
regulatory elements within the Il2 promoter. In agreement with this observation steady-state Il2 mRNA levels
showed no variation between susceptible and resistant mouse strains. These data suggest that the profound
protection from diabetes seen in congenic mice carrying an Idd3 protective allele is unlikely to be due to
differences in the level of expression of the Il2 gene. Instead, all of the current data support our hypothesis that
Idd3 corresponds to amino acid variation at the amino terminus of Il2.
[Sequence data reported in this paper have been deposited in GenBank and assigned the following accession
numbers: AF19594, AF19595, and AF19596.]
Type 1 diabetes results from the autoimmune destruc-
tion of the insulin-producing b cells of the pancreas. A
breakdown in immune homeostasis leads to a lympho-
cytic infiltration of the pancreatic islets of Langerhans,
a process known as insulitis, which in turn progresses
to b-cell destruction and overt disease. Although the
molecular events that initiate and subsequently drive
the process are uncertain it is clear that disease suscep-
tibility is under complex genetic control.
The nonobese diabetic (NOD) mouse model of
type 1 diabetes (Leiter 1998) has greatly facilitated the
genetic dissection of type 1 diabetes. At present, 19 loci
have been mapped that contribute to the development
of type 1 diabetes in the NOD mouse (Leiter 1998;
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Melanitou et al. 1998; Lyons and Wicker 1999). The
approach we have adopted for the fine mapping of
these insulin-dependent diabetes (Idd) susceptibility
loci in the NOD mouse is one of congenic mapping
(Wicker et al. 1994, 1995; Lord et al. 1995; Denny et al.
1997; Podolin et al. 1997).
Using this approach we have previously mapped
the Idd3 locus to a 0.35-cM interval on proximal mouse
chromosome 3 between the microsatellite markers
D3Nds55 and D3Nds40 (Denny et al. 1997). One gene
known to map within this small interval is that encod-
ing the cytokine interleukin-2 (IL2) (Denny et al.
1997). A growing body of evidence makes Il2 a strong
candidate for Idd3. A series of reports have shown that
IL2 plays a central role in the development of self tol-
erance, with a lack of IL2 being associated with the
development of autoimmune disease (Hunig and
Schimpl 1998). It has been shown that IL2 is essential
for activation-induced cell death of T cells mediated
via the Fas pathway, a key mechanism of self-tolerance
(Refaeli et al. 1998). We have shown previously that
sequence polymorphisms exist between IL2 allotypes
from different strains of mice (Ghosh et al. 1993;
Denny et al. 1997) and that these polymorphisms, in
exon 1 of Il2, segregate with susceptibility to diabetes
(Denny et al. 1997). Moreover, one of the polymor-
phisms, the presence of proline rather than serine at
position 6 of the mature IL2 protein, is associated with
both the increased glycosylation of IL2 and diabetes
susceptibility (Podolin et al. 2000). Despite the ob-
served sequence differences between IL2 allotypes
from diabetes-susceptible and -resistant strains no
functional difference has been reported. Although the
Il2 promoter has been well characterized it is unknown
whether variation exists in this region between mouse
strains. Any variant that leads to an alteration in ex-
pression of Il2 would be a strong candidate for the Idd3
etiological mutation. Consistent with this possibility,
reduced secretion of IL2 by mitogen-activated spleno-
cytes has been reported previously in the NOD mouse
(Serreze et al. 1989).
In this study we have refined the genetic mapping
of Idd3 to a 0.15-cM interval that still encompasses the
Il2 gene. We have constructed a physical contig of
mouse BAC clones across the new minimal interval
and by restriction mapping have determined that the
maximum size of the Idd3 interval is 780 kb. Haplotype
analysis in mouse strains known to carry either an Idd3
susceptibility or protective allele identifies the most
likely location of Idd3 as the 145-kb interval between
the microsatellite marker D3Nds6 and the single
nucleotide polymorphism (SNP) 81.3. To identify po-
tential regulatory polymorphisms we sequenced the
promoter region of the Il2 gene from mice carrying
either susceptibility (NOD and 129) or protective (B6)
alleles at Idd3. None of the identified variants within
the Il2 promoter region fell in known regulatory ele-
ments. In agreement with this, no difference was ob-
served in steady-state Il2 mRNA levels, as assessed by
semiquantitative RT–PCR, between mice carrying Idd3
susceptibility or protective alleles.
RESULTS
Generation of New Variant Microsatellite Markers
within the Idd3 Interval
We have described previously the establishment of a
YAC framework map across the Idd3 region (Denny et
al. 1997). To facilitate the isolation of additional poly-
morphic markers from within the Idd3 region we iden-
tified mouse P1 and BAC clones positive for STSs de-
veloped from YACs spanning the Idd3 interval. Mouse
P1 and BAC libraries were screened by PCR with the
following STSs: B1R18STS, D3Nds36, D3Nds47,
D3Nds6, D3Nds56, D3Nds51, D3Nds34, D3Nds46,
D3Nds45, and D3Nds40. Four new microsatellite mark-
ers, D3Nds76, D3Nds77, D3Nds78, and D3Nds84, were
isolated from the clones mP284k17, mP315n15,
mP305l10, and mP88b24, respectively. These new mi-
crosatellite markers were ordered with respect to
D3Nds55, D3Nds6, D3Nds34, D3Nds36, and D3Nds40
by genotyping the 944 progeny of an F2 cross between
NOD and the strain NOD.B62 (Lord et al. 1995). The
following map order was obtained D3Nds55–(0.2 cM)–
D3Nds36–(0.07 cM)–D3Nds84–(0 cM)–D3Nds6–(0 cM)–
D3Nds34–(0.08 cM)– D3Nds76–(0 cM)–D3Nds77–(0
cM)–D3Nds78–(0 cM)–D3Nds40 (Fig. 1). Where the
marker order could not be resolved genetically the or-
der was determined from the Idd3 region physical map.
Narrowing of the Idd3 Interval to 0.15 cM
Previously, we have mapped Idd3 to a 0.35-cM interval
between, but not including, the microsatellite markers
Figure 1 High-resolution genetic map of proximal chromo-
some 3 around Idd3. The lower bars show the genotypes for
markers within the Idd3 interval for the congenic strains NOD. B6
Idd3R450 and NOD. B6 Idd3R808. The solid bars indicate B6-
derived genome and the numbers beside the bars indicate female
diabetes frequencies at 7 months of age. Distances between
markers are given in cM.
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D3Nds55 and D3Nds40 (Denny et al. 1997). To more
precisely map the Idd3 interval, the NOD.B6 Idd3R808
strain was developed from the previously described
NOD.B62 congenic strain (Lord et al. 1995), a strain
that carries the Idd3 resistance allele. Genotyping the
NOD. B6 Idd3R808 strain with polymorphic microsat-
ellite markers that map to the Idd3 interval showed
that it was NOD derived at D3Nds55 and D3Nds36 and
B6 derived at D3Nds84, D3Nds6, D3Nds34, D3Nds76,
D3Nds77, D3Nds78, and D3Nds40 (Fig. 1). This
mapped the proximal boundary of its congenic seg-
ment to the 0.07-cM interval between D3Nds36 and
D3Nds84. The frequency of diabetes in females of this
strain at 7 months is 29.5% (26/88) compared with
25.4% (17/67) in the NOD.B62 strain (P >0.05) and
77.8% (63/81) in NOD (P < 0.0001). Thus, like
NOD.B62, NOD. B6 Idd3R808 carries the Idd3 resis-
tance allele. Because NOD. B6 Idd3R808 carries the Idd3
resistance allele the proximal boundary of Idd3 must lie
in the 0.07-cM interval between the markers D3Nds36
and D3Nds84 (Fig. 1).
The distal boundary of Idd3 is defined by the con-
genic strains NOD.B63 and NOD. B6 Idd3R450 (Lord et
al. 1995). Typing these strains with the newly devel-
oped markers showed that both strains recombine in
the 0.08-cM interval between D3Nds34 and D3Nds76
(Fig. 1). Thus, on the basis of this genotyping data the
size of the Idd3 locus has been reduced to the 0.15-cM
interval between, but not including, the markers
D3Nds36 and D3Nds76 (Fig. 1).
Construction of a BAC Contig Across
the D3Nds36-to-D3Nds76 Interval
A BAC contig covering the minimal Idd3 interval was
constructed as follows. Insert ends of clones, identified
by screening the mouse BAC library with the STSs de-
scribed earlier, were isolated and used to develop new
STSs. These new STSs were then used to rescreen the
library, identifying additional clones that spanned the
gaps between adjacent clusters of clones. A total of 24
clones were isolated that together span the interval be-
tween D3Nds36 and D3Nds76 (Fig. 2).
The size of each clone was determined by restric-
tion enzyme digestion (Fig. 2). Each clone was digested
independently with both NotIA and SalI to eliminate
errors caused by the comigration of bands of similar
size. STSs were assigned to individual Sal1 fragments by
Southern hybridization and used to identify common
Figure 2 Physical map across the Idd3 minimal interval. (A) SalI fingerprints of BAC clones spanning the interval. (B) SalI restriction map
of the Idd3 interval; markers were assigned to specific SalI bands by Southern hybridization. Markers shown in bold are polymorphic
between NOD and B6. The gene content of the Idd3 interval is shown below, where known the orientation of transcription is indicated
by arrowheads (the transcription units are not drawn to scale).
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bands in overlapping clones. Based on the degree of
overlap between individual clones the physical dis-
tance between D3Nds36 and D3Nds76 is 780 kb (Fig.
2). The proximal boundary of Idd3 lies in the 315-kb
interval between D3Nds36 and D3Nds84, whereas its
distal boundary lies in the 65-kb segment between
D3Nds34 and D3Nds76. Thus, the size of the Idd3 locus
is between 400 and 780 kb (Fig. 2).
Refinement of the Idd3 Interval by
Haplotype Mapping
To refine the Idd3 locus using congenic strains would
be impractical given the large number of mice that
would have to be bred to identify new recombinants
within the interval. Therefore, to further narrow the
interval we carried out haplotype analysis on six
mouse strains known to carry either the Idd3 suscepti-
bility or protective allele. On the basis of either linkage
analysis or congenic mapping the strains 129, SWR,
and ABH have been determined to be susceptible at the
Idd3 locus, whereas the B6 and NON strains are diabe-
tes resistant at the locus (Denny et al. 1997; Podolin et
al. 2000).
These strains were genotyped for all the microsat-
ellite markers and SNPs known to be variant between
NOD and B6 that map to the 780-kb Idd3 region (Table
1). In addition, nine more novel SNPs were identified
in the six strains by sequencing STSs derived from BAC
clone ends (Table 1). A comparison of the NOD and
129 mouse strains, both of which carry an Idd3 suscep-
tibility allele, shows that they have identical genotypes
at all of the markers typed with the exception of
D3Nds36 (Table 1). This data confirms the congenic
mapping data and identifies an Idd3-susceptible hap-
lotype. The sequence identity between the two strains
at multiple variable sites indicated the common ances-
try of this segment of DNA between the NOD and 129
strains. Analysis of the two strains that carry an Idd3-
protective allele, namely B6 and NON, reveals that
they also have identical genotypes, but their shared
ancestral haplotype is distinct from that found in sus-
ceptible strains at all markers (Table 1). This identifies
an Idd3-protective haplotype and narrows the Idd3 in-
terval to the 365-kb region between D3Nds84 and
D3Nds76. Analysis of the ABH strain, which has an
Idd3-susceptible allele, shows that it carries the Idd3-
susceptible haplotype between the markers 229.1 and
D3Nds76 (Table 1). These data place the proximal
boundary of Idd3 in the 4-kb interval between the mi-
crosatellite marker D3Nds6 and the SNP 229.1. The
SWR mouse strain has a recombinant haplotype; it has
the susceptible haplotype at the markers 229.1 through
81.2 and the protective haplotype at the markers 81.3
through 51.2 (Table 1). Because SWR has an Idd3-
susceptible allele this gives the most likely location of
Idd3 as the 145-kb region between, but not including,
the microsatellite marker D3Nds6 and the SNP 81.3
(Table 1). As the G allele of the SNP 1694 is carried on
both the protective and susceptible haplotypes it can
be excluded as a candidate for the Idd3 etiological mu-
tation. Of the four genes known to map to the 780-kb
interval, namely Ccna, Tenr, Il2, and Fgf2, only Il2
maps to the 145-kb candidate region.
Analysis of Il2 Gene Expression in Mouse Strains
Carrying Idd3 Susceptibility or Protective Alleles
The promoter regions of the Il2 genes from NOD, B6,
and 129 were sequenced to identify any polymor-
phisms that might lead to differences in transcription
between mice carrying either Idd3 susceptibility or re-
sistance alleles. The B6 promoter sequence was deter-
mined by sequencing a cosmid clone, mC1h5, that
contains the entire IL2 structural gene. Based on this
sequence data PCR primers were designed to amplify
the entire Il2 promoter region from nucleotide 1740
to nucleotide +100. This region has been shown previ-
ously to encompass all the regulatory elements re-
quired for transcription of Il2 (Serfling et al. 1995). Us-
ing this PCR-based approach, the sequences of the
NOD and 129 Il2 promoters were determined and
aligned to that of B6. Two polymorphisms were de-
tected, one at position 1694 the other at position
1674. In both cases the polymorphisms were A-for-G
substitutions, with NOD and 129 having the A allele
and B6 the G allele. In neither case did the polymor-
phism occur in a known transcription factor binding
site.
To extend the evidence against the presence of
functional regulatory allelic variants, the relative levels
of transcription of the NOD, B6, and 129 IL2 genes
were measured. Total RNA from mixtures of either
NOD and NOD.B6 Idd3R450, or NOD.B6 Idd3R450 and
NOD.129 Idd3 splenocytes stimulated with ionomycin
and PMA was used as the template for RT–PCR ampli-
fication with the microsatellite marker D3Mit21.
D3Mit21 amplifies a variant CAG repeat in exon 1 of
Il2. The relative amount of RNA from each allele was
quantified by analyzing the fluorescently labeled PCR
products on an ABI 373 automated sequencer and cal-
culating the ratio of the two products. As a control for
preferential amplification genomic DNA was amplified
with D3Mit21 at the same time. No difference was ob-
served in the steady state level of Il2 RNA from either
the NOD or the 129 allele compared with that from the
B6 allele (ratio of NOD Il2 RNA to B6 Il2 RNA equals
0.89 5 0.12 and ratio of 129 Il2 RNA to B6 Il2 RNA
equals 1.06 5 0.07, Fig. 3). Taken together with the
sequencing data this suggests that the reduction in dia-
betes conferred by Idd3-protective alleles is not due
to differences in the level of transcription of the Il2
gene.
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DISCUSSION
The publication of the results of genome-wide scans for
type 1 diabetes susceptibility genes in both the NOD
mouse and humans (Todd et al. 1991; Ghosh et al.
1993; Davies et al. 1994; Hashimoto et al. 1994; Con-
cannon et al. 1998; Mein et al. 1998) has raised expec-
tations that within a few years we will know the iden-
tity of the genes that predispose to the disease, have a
better understanding of the pathological mechanisms
underlying it, and, as a result, have identified targets
for therapeutic intervention. Although the fine map-
ping of diabetes susceptibility genes in humans awaits
further advances in technology, the genome sequence,
a catalog of SNPs, and additional DNA samples from
larger patient collections, fine mapping in the NOD
mouse has proved more tractable (Lyons and Wicker
1999).
A number of experimental strategies for fine map-
ping quantitative trait loci (QTL) in mice have been
proposed (reviewed in Darvasi 1998). The approach we
have adopted to fine map Idd loci in the NOD mouse is
one based on the congenic strategy pioneered by Snell
in the 1940s during his work on the H2 locus (Snell
1948). Over the past 5 years we have described the
production of a series of congenic strains that, initially,
confirmed the linkage mapping of Idd3 and, subse-
quently, systematically fine mapped it to a 0.35-cM
interval (Wicker et al. 1994; Lord et al. 1995; Denny et
al. 1997). In this study we describe the mapping of the
Idd3 locus to a 780-kb interval. This is the first time
congenic mapping has been used to map a QTL to an
interval less than one megabase in size, confirming the
power of the congenic strategy to map loci to intervals
amenable to systematic gene identification. Ulti-
mately, two factors limit the resolving power of con-
genic mapping: the density of the genetic map in the
region of interest and the ability to generate and screen
large populations of mice.
The current microsatellite map of the mouse ge-
nome is dense enough that variant markers between
any two inbred mouse strains can be found approxi-
mately every centimorgan. To achieve a greater resolu-
tion will in most cases require, as was the case for Idd3,
the generation of novel, interval-specific markers,
which is a time-consuming process. The production of
a dense, evenly-spaced SNP map, similar to that cur-
rently being generated in man, would greatly alleviate
this problem and speed the mapping process.
The numbers of mice required to reduce a con-
genic interval to any particular size can be theoretically
determined (Darvasi 1997). In theory to reduce an in-
terval from 4 cM to 0.15 cM would require the screen-
ing of ~ 1300 mice. The screening of this number of
mice is a realistic proposition; in fact in the present
study we screened 944 F2 mice to identify the two re-
combinant events that reduce the Idd3 interval to 0.15
cM. To achieve a similar level of resolution (with a 95%
confidence interval) using a conventional intercross
strategy would require 40,000 F2 progeny to be
screened.
An alternative strategy for the fine mapping of
QTL to interval sizes amenable to positional cloning
has been described recently (Talbot et al. 1999). This
approach uses an outbred stock of mice derived >30
years ago from an eight-way cross of inbred mouse
strains and in theory has a 30-fold increase in resolving
power when compared to a conventional F2 cross.
However, the general applicability of this approach to
fine mapping QTL is debatable as the ability to detect
QTL is extremely sensitive to the allele distribution
among the eight parental strains at each marker. More-
over, the approach can only map the QTL into a sta-
tistically defined confidence interval. The congenic ap-
proach on the other hand produces a defined interval
that must contain the QTL. Furthermore, the strategy
of Talbot et al. (1999) would be compromised if there
were two closely linked but separate loci in the region
under the linkage curve.
Once an interval has been mapped to a size such
that markers can be positioned relative to each other
with some precision haplotype, mapping becomes a
powerful tool to refine the interval size. By identifying
chromosome regions shared identical by descent (IBD)
it is possible to use ancestral recombination events to
provide additional mapping information. One impor-
tant assumption is that all strains carrying a suscepti-
Table 1. Genotypes at Microsatellite and SNP Markers Across the Idd3 Interval in Mouse Strains Possessing Either Idd3 Susceptibility or
Protective Alleles
Strain
Marker
D3Nds36 D3Nds84 D3Nds6 229.1 229.2 D3Mit21 SSPT aa6 2674 2694 56.1 81.1 81.2 81.3 81.4 81.5 81.7 51.2 D3Nds34 D3Nds76
NOD 230.55 115.35 106.95 G A 218.81 + P A A G T G - A T T T 174.87 133.16
129 222.23 115.43 106.84 G A 218.98 + P A A G T G - A T T T 174.78 133.18
NON 212.62 131.44 139.92 T G 230.67 - S G G A C A + G C C C 196.17 133.21
B6 212.59 137.34 139.77 T G 230.74 - S G G A C A + G C C C 196.17 129.18
ABH 238.24 112.76 135.9 G A 218.92 + P A G G T G - A T T T 174.93 133.13
SWR 222.51 118.29 132.24 G A 218.89 + P A G G T G + G C C C 182.67 133.2
| ‹ 145 kb fi|
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bility or protective allele at a particular locus carry the
same allele. Given the observed degree of allele sharing
IBD among the susceptible and resistant strains em-
ployed in the present study this assumption is likely to
be valid for the Idd3 locus. Given the size of the inter-
val and marker density it is likely that the observed
allele sharing is IBD and not merely identical by state
(IBS). If the observed sharing were to be IBS it would
invalidate this approach. Another assumption is that
within the 0.15-cM interval there is only one locus
responsible for the Idd3 effect.
The Il2 gene, the only gene currently known to lie
within the 145-kb minimal interval, is a very strong
candidate for Idd3. Mice that are deficient in the action
of IL2, either through the targeted disruption of the Il2
structural gene itself or the genes encoding the a or b
chains of its receptor, develop a variety of autoimmune
diseases (Hunig and Schimpl 1998). Studies in IL2 and
IL2 receptor knockout mice have shown that the cyto-
kine plays a nonredundant role during Fas-mediated
apoptosis of activated T cells, one of the central pro-
cesses in immune homeostasis (Van Parijs et al. 1997;
Refaeli et al. 1998). Variants within the coding or regu-
latory elements of the Il2 gene that alter the expression
or function of IL2 would be strong candidates for the
Idd3 etiological mutation.
As described in this study we found no evidence of
regulatory variants that alter the expression of the Il2
gene, however, sequence variation has been described
previously in the coding sequence of IL2 allotypes
from different mouse strains (Chesnut et al. 1993;
Ghosh et al. 1993; Matesanz and Alcina 1996, 1998;
Denny et al. 1997). One sequence variant, a proline/
serine substitution at position 6 of the mature IL2 pro-
tein, has been shown to correlate with diabetes suscep-
tibility or resistance at Idd3. Mouse strains carrying an
Idd3 susceptibility allele, such as NOD or 129, have a
proline, whereas strains carrying an Idd3-protective al-
lele, such as B6, have a serine (Denny et al. 1997; Po-
dolin et al. 2000). We have shown recently that differ-
ent IL2 allotypes have different glycosylation profiles
and that this also correlates with the presence or ab-
sence of proline at position 6 (Podolin et al. 2000).
Although these glycosylation differences have no ef-
fect on the ability of IL2 to stimulate proliferation of
IL2-dependent cell lines (Podolin et al. 2000) it is con-
ceivable that they may affect the half-life of the mol-
ecule leading to a functional deficiency in circulating
IL2. It has been shown recently that IL2 can bind to
heparan sulfate in vivo and that this bound IL2 is func-
tional in both promoting T-cell activation and stimu-
lating activation-induced cell death (Wrenshall and
Platt 1999). This binding to heparan sulfate may well
be altered by differences in glycosylation, thereby in-
fluencing in vivo availability of IL2.
Using a combination of congenic mapping and
haplotype analysis we have narrowed the most likely
location of Idd3 to a 145-kb segment of DNA that con-
tains the variant Il2. Although our genetic mapping
data does not conclusively prove that the Il2 gene is
Idd3, the current lack of evidence for a functional dif-
ference between IL2 allotypes from mouse strains with
Idd3 susceptibility or protective alleles does not ex-
clude it. Ultimately, the only definitive way to estab-
lish whether Il2 is Idd3 will be to construct a “knock-
in” mouse in which Il2 from NOD is replaced with the
variant gene from a diabetes-resistant mouse such as B6.
METHODS
Animals
NOD/MrkTacfBR (NOD) mice were purchased from Taconic
Farms, Inc. (Germantown, NY). The following congenic
strains were used in this study: NOD.B62 (N11F2-3), NOD.B63
(N11F2-3), NOD. B6 Idd3R450 (N13F2-3), NOD. B6 Idd3R808
(N13F2-3), and NOD.129 Idd3 (N6F2-4). The derivation of
congenic strains NOD.B62, NOD.B63, NOD. B6 Idd3R450, and
NOD.129 Idd3 has been described previously (Lord et al. 1995;
Denny et al. 1997; Podolin et al. 2000). The NOD. B6
Idd3R808 congenic strain was developed by backcrossing
NOD.B62 to NOD and intercrossing the resulting F1 progeny.
The F2 progeny were genotyped with markers within the Idd3
interval and appropriate recombinants backcrossed to NOD.
Suitable F1 progeny were intercrossed to produce homozygous
animals. The congenic strain was maintained by brother–
sister mating. All mice were housed under sterile, specific
pathogen-free conditions.
Assessment of Diabetes
Mice were monitored for the development of diabetes as de-
scribed previously (Wicker et al. 1994).
STS Mapping and Isolation of Novel Microsatellites
Mouse BAC (Research Genetics) and P1 Imperial Cancer Re-
Figure 3 Transcriptional analysis of the Il2 gene from mouse
strains carrying either Idd3 susceptibility or protective alleles.
Relative Il2 mRNA levels were determined by semiquantitative
RT–PCR.
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search Foundation libraries were screened by PCR according
to the suppliers’ instructions. Clone insert ends were rescued
by vectorette PCR and STSs developed as described previously
(Denny et al. 1997). Novel microsatellite markers were iso-
lated from P1 clones using a PCR-based vectorette approach as
described previously (Merriman et al. 1997). Primer sequences
for the microsatellite and STS markers described in this paper
are available on the web at http://diesel.cimr.cam.ac.uk/todd.
PCR Analysis
STS, fluorescent, and nonfluorescent PCR reactions were per-
formed and analysed as described previously (Denny et al.
1997).
Restriction Enzyme Mapping of BAC Clones
BAC DNA was prepared using a standard alkaline-lysis proto-
col. Aliquots of 1 µg of BAC DNA were digested for 1 hr at
37°C with 10 units of either NotIA or SalI. Following digestion,
DNA fragments were separated by pulsed-field gel electropho-
resis. Gels were run at 200 V for 15.2 hr at 14°C with pulse
times ramped from 0.2 sec to 21.8 sec. Following electropho-
resis and visualization by ethidium bromide staining, DNA
fragments were transferred to nylon filters by capillary action
and fixed by UV cross-linking. Filters were hybridized with
[g-32P]-labeled oligonucleotides.
Il2 Promoter Sequencing
The cosmid mC1h5 was sequenced using a random shotgun
approach essentially as described in Bankier et al (1987). Se-
quence data was assembled using the program GAP4 (Bonfield
et al. 1995). This sequence data has been submitted to Gen-
Bank and assigned the accession number AF19596. Two sets
of PCR primers were designed to amplify the Il2 promoter.
IL2.Pro1 (58-ATGAAAGTGCAACTAGAGCAC-38) and IL2.Pro3
(58-GAGACACAAAAGTAACTCATG-38) give a 444-bp product
spanning nucleotides 3773–4217 of the mC1h5 sequence and
IL2.Pro2 (58-CTTTTCATCTATCTCCTCTTGC-38) and IL2.Pro4
(58-GACAAGGAGCACAAGTGTCAAT-38) amplify a 500-bp
product spanning nucleotides 4115–4615. Following amplifi-
cation, PCR products were gel purified and then sequenced,
with the amplification primers, using an ABI Prism dye ter-
minator cycle sequencing kit (PE Biosystems, Warrington,
UK) according to the manufacturer’s instructions. Sequence
data for the NOD and 129 Il2 promoter regions have been
submitted to GenBank and assigned the accession numbers
AF19594 and AF19595, respectively.
Generation of IL2-Containing Splenocyte Cultures
One million mouse spleen cells were stimulated with 10 ng/
ml of PMA and 400 ng/ml of ionomycin (Calbiochem, San
Diego, CA) for 4 hr as described previously (Chen et al. 1994).
Quantification of Il2 mRNA Levels
Total RNA was extracted from 4 2 107 splenocytes stimulated
with ionomycin and PMA as described above using an RNeasy
RNA extraction kit (Qiagen, Crawley, UK) following the
manufacturer’s instructions. First-strand cDNA was synthe-
sized from 1 µg of total RNA using a M-MLV H1 RT cDNA
synthesis kit (Life Technologies, Glasgow, UK) according to
the manufacturers instructions. The cDNA was diluted 1/100
and 1 µl was used as template for amplification with D3Mit21
(primer sequences for this microsatellite marker are available
on the web at http://www-genome.wi.mit.edu/cgi-bin/
mouse/index). Following amplification the fluorescently la-
beled PCR products were analyzed on an ABI373 automated
sequencer as described previously (Denny et al. 1997). The
amount of Il2 mRNA was quantified using Genotyper soft-
ware (PE Biosytems).
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